Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J-MIND: Tafasitamab ± Lenalidomide/Parsaclisib With or Without R-CHOP in Japanese Non-Hodgkin Lymphoma
jRCT2031200357Phase 2Active, not recruiting
- Sponsor
- Incyte
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tafasitamab in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and 1 more (6 arms), sponsored by Incyte. Started Dec 2020; status: active, not recruiting.
02
Drugs
tafasitamab
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on jRCT2031200357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200357.